Shamburg News · 8-K filed Nov 12, 2026, 4:08 PM EST
Erasca Reports Third Quarter 2026 Results and Business Updates
ERAS · Erasca, Inc.
- Earnings
- Financial statements
- Materiality: high
Erasca, Inc. reported financial results for the three months ended September 30, 2026, with a net loss of $51.3 million, or $(0.15) per basic and diluted share, compared with a net loss of $30.6 million, or $(0.11) per share, a year earlier. R&D expenses were $47.2 million and G&A expenses were $12.3 million for the quarter. Cash, cash equivalents, and marketable securities were $947.8 million as of September 30, 2026, and the company reported that the FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-458350.
Written from the filing by Shamburg Markets. Figures are as reported by the company.